A PHASE 1, OPEN-LABEL DOSE-FINDING AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN 5 TO 12 YEARS OF AGE
Clinical Trial Grant
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
March 10, 2021
End Date
April 15, 2024
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
March 10, 2021
End Date
April 15, 2024